Increased plasma level of terminal complement complex in AMD patients: potential functional consequences for RPE

Catharina Busch1, Saskia Rau2, Andjela Sekulic2

  • 1Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

PubMed

Insights

Higher terminal complement complex (TCC) levels in age-related macular degeneration (AMD) patients correlate with RPE cell pro-inflammatory responses. This suggests a significant role for elevated TCC in AMD pathogenesis, independent of genetic risk factors.

Area of Science:

  • Ophthalmology
  • Immunology
  • Genetics

Background:

  • Polymorphisms in complement genes are associated with age-related macular degeneration (AMD) risk.
  • Risk-associated polymorphisms lead to impaired control of the alternative complement pathway.

Purpose of the Study:

  • Investigate terminal complement complex (TCC) levels in wet AMD patients.
  • Determine the impact of AMD patient plasma complement activation on retinal pigment epithelium (RPE) cells.

Main Methods:

  • Plasma collection from 87 wet AMD patients and 86 controls.
  • Genotyping for risk alleles (CFH 402HH, ARMS2 rs3750846) and TCC level determination.
  • In vitro analysis of RPE function, including Ca2+ imaging and gene/cytokine expression.

Main Results:

  • AMD patients had fivefold higher plasma TCC levels than controls, irrespective of genetic risk alleles.
  • Patient plasma induced distinct Ca2+ signaling in RPE cells, correlating with TCC levels.
  • Exposure to AMD patient plasma sensitized RPE cells, increasing pro-inflammatory cytokine secretion and protective gene expression.

Conclusions:

  • Elevated plasma TCC levels are a significant factor in AMD pathology.
  • AMD patient plasma induces a pro-inflammatory RPE phenotype and protective responses against TCC.
  • The observed effects were independent of common AMD genetic risk factors.
Abstract